搜索
Search
img
专注于大量未被满足临床需求的疾病领域
PREV
NEXT
苏州开拓药业股份有限公司
苏州开拓药业股份有限公司

About Us

Kintor Pharmaceuticals focuses on developing drugs for androgen-receptor-related diseases with significant unmet medical needs,

including prostate cancer, breast cancer, liver cancer, COVID-19, alopecia, acne, and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

这是描述信息
这是描述信息

Small-molecule  drugs

Kintor Pharmaceuticals product pipeline initially focused on androgen receptor (AR) antagonists. Our expanded pipeline now includes mTOR inhibitors, Hedgehog inhibitors, AR protein degradation agents, and cMyc inhibitors.

这是描述信息

Innovative biologics

Kintor Pharmaceuticals' first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers. 

这是描述信息

Combination  therapies

To provide the best treatment for prostate, breast, and liver cancers and other diseases, Kintor Pharmaceuticals is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

R&D Platform

 Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a multidisciplinary team of drug developers.

Manufacturing Base

Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing base in Suzhou.

Commercial Operation

 In anticipation of the commercial launch of our products, Kintor Pharmaceuticals is building an independent commercialization team. [entity?]

R&D Platform

 We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.

Manufacturing Base

A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.

Commercial Operation

 In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.

News Center

2021-06-15

Proxalutamide's Pivotal Study of Treating COVID-19 Male Outpatients Sponsored by Kintor was Approved by ANVISA and CONEP in Brazil

Suzhou, June 15, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved the phase III clinical trial of proxalutamide to treat male patients with mild or moderate COVID-19 symptoms on June 11, 2021[1].

2021-05-18

Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19

Suzhou, May 18, 2021 - Kintor Pharmaceutical Limited (HKEX.9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's phase III clinical trial of hospitalised COVID-19 patients to be conducted, which will recruit both male and female patients. Separately, the FDA agreed to the addition of female patients to its ongoing proxalutamide phase III clinical trial in outpatients with mild to moderate COVID-19 illness. The company will publish and update details of these pivotal studies at ClinicalTrials.gov.

2021-05-16

Kintor Appointed Dr. Qun Lu as CTO and Dr. Jiawen Han as BD VP

Suzhou, China, May 16, 2021 —Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the appointment of Dr. Qun Lu as the Chief Technology Officer (CTO) and Dr. Jiawen Han as vice president of business development. Dr. Lu will be primarily responsible for Chemistry, Manufacturing, and Control (the “CMC”) including drug analysis, formulation development and the production. Dr. Han will be primarily responsible for business development-related projects and management. Both of Dr. Lu and Dr. Han will be reporting to Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharmaceuticals.

Work at Kintor

这是描述信息
这是描述信息